About the Cancer Drug Discovery, Targeted Therapy & ADCs Session
Advances in molecular understanding of cancer continue to drive the development of increasingly selective and effective treatments. This session focuses on anticancer drug discovery, targeted therapies, small molecules, antibody-based approaches, antibody-drug conjugates, bispecific antibodies, novel delivery systems, and mechanisms of treatment resistance.
Abstract Scope and Participation
Abstracts are invited on drug discovery, targeted therapy, small-molecule inhibitors, monoclonal antibodies, ADCs, bispecific antibodies, drug delivery, nanomedicine, pharmacology, resistance mechanisms, and therapeutic optimization. Academic researchers, clinicians, pharmacologists, biotechnology scientists, and pharmaceutical professionals are encouraged to participate.
Topics Covered in Cancer Drug Discovery, Targeted Therapy & ADCs
Topic 01
Drug Discovery
Topic 02
Targeted Therapy
Topic 03
Small Molecules
Topic 04
Antibody-Drug Conjugates
Topic 05
Bispecific Antibodies
Topic 06
Drug Resistance
Featured Speakers — Cancer Drug Discovery, Targeted Therapy & ADCs 2027
Recent Research Presented at Cancer Drug Discovery, Targeted Therapy & ADCs Sessions
AI-guided optimization and structure-based virtual screening identify novel dual-state KRAS G12D inhibitor candidates
Background: KRAS G12D is one of the most prevalent oncogenic drivers in pancreatic and colorectal cancers and remains a challenging therapeutic target because of its high affinity for GTP and the…
Bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of EGFR-TKI acquired resistant advanced lung adenocarcinoma
Objective: To compare the short-term therapeutic efficacy and safety of bevacizumab versus anlotinib, each in combination with chemotherapy, for the treatment of advanced lung adenocarcinoma with…
Phytohormone strigolactams overcome oxaliplatin resistance in colorectal cancer by blocking late-stage autophagy to tip the metabolic balance toward ferroptosis
My presentation addresses one of the most pressing challenges in oncology: Treatment Resistance. I will focus on a novel strategy to overcome oxaliplatin resistance in colorectal cancer, titled "…
Temporal changes in HER2 and nectin4 expression in urothelial carcinoma: Implications for antibody–drug conjugate therapy
Background: Urothelial carcinoma is frequently managed with chemotherapy combined with immunotherapy or antibody-drug conjugates (ADCs) targeting HER2 and Nectin4, which have shown promising efficacy…
Unveiling etiological mechanisms and a targeted, non-toxic integrative approach for cancer management
Cancer has emerged as a major global public health challenge, affecting populations across all age groups. Once considered a rare and inexplicable disease, advances in biomedical sciences have…
Investigation of new synthetic compounds: 4-(methyl sulfanyl) phenyl-1,3,4-thiadiazol-2-amine and 1-methyl-[4-(methyl sulfanyl)phenyl]-1,3,4-thiadiazol-2-amine, for anti-cancerous activity and for p53 anti-cancer gene expression on glioblastoma cell cultures (LN-229)
Glioblastoma Multiforme (GBM) is a stage IV brain tumour is complex and deadly diseases. There is no promising therapeutic applications for GBM, and so many drugs are developed, and screened in pre…
Related Scientific Sessions at CIOC 2027
Why Attend the Cancer Drug Discovery, Targeted Therapy & ADCs Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Cancer Drug Discovery, Targeted Therapy & ADCs work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Cancer Drug Discovery, Targeted Therapy & ADCs research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Cancer Drug Discovery, Targeted Therapy & ADCs track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Cancer Drug Discovery, Targeted Therapy & ADCs Conference 2027 — FAQs
What is the Cancer Drug Discovery, Targeted Therapy & ADCs track at CIOC 2027?
The Cancer Drug Discovery, Targeted Therapy & ADCs track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Cancer Drug Discovery, Targeted Therapy & ADCs. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Cancer Drug Discovery, Targeted Therapy & ADCs sessions?
Cancer researchers and clinicians, educators and students with an interest in Cancer Drug Discovery, Targeted Therapy & ADCs are all welcome — whether presenting or attending.
Can I present my research in the Cancer Drug Discovery, Targeted Therapy & ADCs track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Cancer Drug Discovery, Targeted Therapy & ADCs sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Cancer Drug Discovery, Targeted Therapy & ADCs track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Register as Delegate →
Attend without presenting.